Citigroup Inc. lifted its position in shares of Radius Health, Inc. (NASDAQ:RDUS) by 4,540.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 49,053 shares of the biopharmaceutical company’s stock after buying an additional 47,996 shares during the quarter. Citigroup Inc. owned approximately 0.11% of Radius Health worth $2,219,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Radius Health by 3.2% during the first quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock worth $116,362,000 after buying an additional 93,188 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after buying an additional 262,896 shares in the last quarter. Pictet Asset Management Ltd. grew its holdings in shares of Radius Health by 20.0% during the second quarter. Pictet Asset Management Ltd. now owns 641,388 shares of the biopharmaceutical company’s stock worth $22,205,000 after buying an additional 106,849 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Radius Health during the second quarter worth about $25,589,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Radius Health by 19.3% during the second quarter. Bank of New York Mellon Corp now owns 529,865 shares of the biopharmaceutical company’s stock worth $23,965,000 after buying an additional 85,816 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Citigroup Inc. Purchases 47,996 Shares of Radius Health, Inc. (RDUS)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/28/citigroup-inc-purchases-47996-shares-of-radius-health-inc-rdus.html.

A number of equities research analysts have recently commented on RDUS shares. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, July 31st. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the stock a “buy” rating in a report on Sunday, June 4th. Finally, Jefferies Group LLC set a $34.00 price target on shares of Radius Health and gave the stock a “hold” rating in a report on Monday, June 5th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.60.

In related news, major shareholder Growth N. V. Biotech acquired 60,000 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were purchased at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the acquisition, the insider now owns 5,248,799 shares in the company, valued at $188,851,788.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were bought at an average price of $34.97 per share, for a total transaction of $5,245,500.00. Following the acquisition, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 469,100 shares of company stock worth $16,328,382. Corporate insiders own 15.00% of the company’s stock.

Shares of Radius Health, Inc. (NASDAQ:RDUS) opened at 37.85 on Thursday. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $59.22. The firm’s market capitalization is $1.65 billion. The company has a 50 day moving average of $36.80 and a 200 day moving average of $38.96.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter in the previous year, the firm posted ($1.01) EPS. On average, analysts anticipate that Radius Health, Inc. will post ($5.58) earnings per share for the current fiscal year.

Radius Health Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.